Skip to content

Iovance Biotherapeutics

US · IOVA #1864 by market cap Listed 1970
6.90 -0.41 -5.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Recent news

  • Rating change
    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/9/17
  • Rating change
    Jefferies Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/10/24
  • Rating change
    H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/6/4
  • Earnings Flash (IOVA) Iovance Biotherapeutics, Inc. Reports Q3 Revenue $121.5M, Vs. FactSet Est of $116.0M
    MT Newswires · 2026/11/5
  • Rating change
    Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/2/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)
    TipRanks · 2026/4/22
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/10/30
  • Rating change
    TD Cowen Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2026/8/25
  • Rating change
    Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $8
    Market Newswire · 2026/8/8
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $15 to $20
    Market Newswire · 2026/9/30
  • H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/11/11
  • Rating change
    Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/4/11
  • Rating change
    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2026/7/20
  • Rating change
    Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/8/18
  • Rating change
    Goldman Sachs Upgrades Iovance Biotherapeutics(IOVA.US) to Buy Rating, Raises Target Price to $15
    Market Newswire · 2026/9/24
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13
    Market Newswire · 2026/8/7
  • Rating change
    A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14
    Market Newswire · 2026/5/8
  • Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/11/6
  • Rating change
    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2026/10/13
  • Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $19
    Market Newswire · 2026/11/6
  • Rating change
    Baird Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $4
    Market Newswire · 2026/2/25
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Erasca (ERAS) and Tempus AI, Inc. Class A (TEM)
    TipRanks · 2026/2/25
  • Rating change
    Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating
    Market Newswire · 2026/2/25
  • H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/10/30
  • Rating change
    Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Sell Rating, Raises Target Price to $2
    Market Newswire · 2026/2/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:59:47 · For reference only, not investment advice and not tailored to your situation.

Iovance Biotherapeutics discussion 0 comments

Add a comment